Frank Lammert,Henning Wittenburg
Frank Lammert
Gallstones are common and affect up to 20% of the general adult population and >20% of them will develop symptoms or complications of cholelithiasis. The high risk of gallbladder stone formation can be reduced by ursodeoxycholic acid in the...
Maria Pilar Ballester,Esra Nur Durmazer,Tingting Qi et al.
Maria Pilar Ballester et al.
Ammonia is a product of amino acid metabolism that accumulates in the blood of patients with cirrhosis and plays a pivotal role in the pathogenesis of hepatic encephalopathy (HE). Despite being one of the main drivers of brain dysfunction, ...
Ingrid Wei Zhang,Isabella Lurje,Georg Lurje et al.
Ingrid Wei Zhang et al.
Transplantation of the liver in combination with other organs is an increasingly performed procedure. Over the years, continuous improvement in survival could be realized through careful patient selection and refined organ preservation tech...
Application of Novel Biomarkers in MASLD: Precision Medicine Based Approach [0.03%]
新型生物标志物在MASLD中应用的精准医学方法学研究
Nimish Thakral,Hailemichael Desalegn,Luis Antonio Diaz et al.
Nimish Thakral et al.
The new nomenclature of metabolic dysfunction-associated steatotic liver disease (MASLD) emphasizes a positive diagnosis based on cardiometabolic risk factors (CMRFs). This definition is not only less stigmatizing but also allows for subcla...
Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis [0.03%]
评估代谢异常相关肝脂肪变性及其炎症性疾病纤维化和病情严重程度的无创检测方法
Monica A Tincopa,Rohit Loomba
Monica A Tincopa
Risk of disease progression and clinical outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with fibrosis stage and presence of "at-risk metabolic dysfunction-associated steatohepatitis (MASH)." Altho...
Cheng Chen,Dechun Feng,Yang Wang et al.
Cheng Chen et al.
The liver has the great ability to regenerate after partial resection or injury, and the mechanisms underlying liver regeneration have been extensively investigated. Interestingly, acute liver injuries triggered by various etiologies are as...
Manasi Kotulkar,Diego Paine-Cabrera,Udayan Apte
Manasi Kotulkar
Liver cancer is the sixth most common cancer and the fourth leading cause of cancer-related deaths worldwide. Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer and the incidence of HCC is on the rise. Liver cancers i...
Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future [0.03%]
肝细胞癌肝脏移植的补遗：综述及未来展望
Hao Liu,Vrishketan Sethi,Xingjie Li et al.
Hao Liu et al.
Published Erratum
Seminars in liver disease. 2024 Feb;44(1):e1-e3. DOI:10.1055/s-0044-1787737 2024
Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets [0.03%]
脂肪性肝病的炎症：发病机制和治疗靶点
Shengying Qian,Xiaolin Wang,Yingfen Chen et al.
Shengying Qian et al.
Alcohol-related liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), two main types of steatotic liver disease (SLDs), are characterized by a wide spectrum of several different liver disorders, including...
Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together? [0.03%]
联合治疗克服肝癌免疫检查点抑制抵抗：1+1＞2？
Wiebke Werner,Maria Kuzminskaya,Isabella Lurje et al.
Wiebke Werner et al.
Primary liver cancer, represented mainly by hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CCA), is one of the most common and deadliest tumors worldwide. While surgical resection or liver transplantation are the best o...